ClinicalTrials.gg
RecruitingNCT06292780LINKER-AL2Updated Aug 18, 2026

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

A Phase 1/2 interventional study of Linvoseltamab in Relapsed/Refractory Systemic Light Chain Amyloidosis, sponsored by Regeneron Pharmaceuticals. Recruiting at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
220
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is researching an experimental drug called linvoseltamab ("study drug").

This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again.

The study consists of 2 phases (Phase 1 and Phase 2):

  • In Phase 1, linvoseltamab will be given to a small number of participants to study the side effects of the study drug and to determine the recommended doses of the study drug to be given to participants in Phase 2.
  • In Phase 2, linvoseltamab will be given to more participants to continue to assess the side effects of the study drug and to evaluate the ability of linvoseltamab to treat AL amyloidosis.

The study is looking at several other research questions, including:

  • How many participants treated with linvoseltamab have improvement in the abnormal proteins that cause organ problems and for how long
  • How many participants treated with linvoseltamab have improvement in the heart or kidney and for how long
  • What the right dosing regimen is for linvoseltamab
  • What side effects may happen from taking linvoseltamab
  • How much linvoseltamab is in the blood at different times
  • Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects)
02

Conditions studied

  • Relapsed/Refractory Systemic Light Chain Amyloidosis

Browse trials for

Keywords

  • Amyloid light-chain (AL)
  • Multiple Myeloma (MM)
  • Pathogenic light chains
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Confirmed diagnosis of AL amyloidosis, as described in the protocol
  2. as defined by serum difference between involved and uninvolved free light chains (dFLC) concentration, as described in the protocol
  3. Previously treated after at least 1 prior therapy and requiring further treatment as assessed by the Investigator
  4. N-terminal pro b-type natriuretic peptide (NT-proBNP) ≤8500 ng/L during screening
  5. Adequate hepatic, hematologic, renal, and cardiac function, as described in the protocol
  6. (ECOG) performance score ≤2 at screening

Key Exclusion Criteria:

  1. History of other non-AL amyloidosis
  2. Greater than 60% plasmacytosis on a bone marrow and/or aspirate during screening
  3. Presence of lytic bone lesion(s) or extramedullary plasmacytoma on imaging during screening
  4. Myocardial infarction within the past 6 months prior to the first screening visit
  5. Known active infection requiring hospitalization or treatment with IV anti-infectives within 28 days of first administration of study drug

NOTE: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Phase 1: Cohort 1: Low Dose

    Dose Escalation: Non-Randomized

    Drug: Linvoseltamab

  • Experimental
    Phase 1: Cohort 2: High Dose

    Dose Escalation: Non-Randomized

    Drug: Linvoseltamab

  • Experimental
    Phase 2: Low Dose

    Dose Expansion: Participants will be randomized in a 1:1 ratio

    Drug: Linvoseltamab

  • Experimental
    Phase 2: High Dose

    Dose Expansion: Participants will be randomized in a 1:1 ratio

    Drug: Linvoseltamab

Interventions

  • anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody

    Also known as: REGN5458, Lynozyfic™

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicity (DLTs)

    Phase 1

    Time frame: Up to 28 Days

  2. Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)

    Phase 2

    Time frame: Up to 3 years

Secondary outcomes

  1. Achievement of hematologic CR, as determined by the IRC

    Phase 1

    Time frame: Up to 3 years

  2. Achievement of hematologic very good partial response (VGPR) or better response (CR + VGPR), as determined by the IRC

    Time frame: Up to 3 years

  3. Achievement of overall hematologic response (PR or better), as determined by the IRC

    Time frame: Up to 3 years

  4. Time to initial hematologic response

    Time frame: Up to 3 years

  5. Time to best hematologic response

    Time frame: Up to 3 years

  6. Duration of hematologic response (ie, best response, VGPR or better, overall response), as determined by the IRC

    Time frame: Up to 7 years

  7. Hematologic progression-free survival (PFS)

    Time frame: Up to 7 years

  8. Incidence of death

    Time frame: Up to 7 years

  9. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 39 months

  10. Severity of TEAEs

    Time frame: Up to 39 months

  11. Incidence of serious adverse events (SAEs)

    Time frame: Up to 39 months

  12. Severity of SAEs

    Time frame: Up to 39 months

  13. Incidence of adverse events of special interest (AESIs)

    Time frame: Up to 39 months

  14. Severity of AESIs

    Time frame: Up to 39 months

  15. Achievement of overall hematologic response (PR or better), as determined by the IRC in dose regimen 1 vs 2

    Phase 2

    Time frame: Up to 39 months

  16. Incidence of TEAEs in dose regimen 1 vs 2

    Phase 2

    Time frame: Up to 39 months

  17. Severity of TEAEs in dose regimen 1 vs 2

    Phase 2

    Time frame: Up to 39 months

  18. Incidence of SAEs in dose regimen 1 vs 2

    Phase 2

    Time frame: Up to 39 months

  19. Severity of SAEs in dose regimen 1 vs 2

    Phase 2

    Time frame: Up to 39 months

  20. Incidence of AESIs in dose regimen 1 vs 2

    Phase 2

    Time frame: Up to 39 months

  21. Severity of AESIs in dose regimen 1 vs 2

    Phase 2

    Time frame: Up to 39 months

  22. Time from treatment initiation to hematologic disease progression as determined by the IRC

    Time frame: Up to 7 years

  23. Time from treatment initiation to cardiac deterioration, as determined by the IRC

    Time frame: Up to 7 years

  24. Time from treatment initiation to kidney deterioration as determined by the IRC

    Time frame: Up to 7 years

  25. Time from treatment initiation to death as determined by the IRC

    Time frame: Up to 7 years

  26. Time from initiation of treatment to date of death from any cause

    Time frame: Up to 7 years

  27. Achievement of renal response in participants with renal involvement at baseline, as determined by IRC

    Time frame: Up to 7 years

  28. Achievement of cardiac response in participants with cardiac involvement at baseline, as determined by IRC

    Time frame: Up to 7 years

  29. Time to first renal response in participants with renal involvement at baseline

    Time frame: Up to 7 years

  30. Time to first cardiac response in participants with cardiac involvement at baseline

    Time frame: Up to 7 years

  31. Linvoseltamab concentration in serum over time

    Time frame: Up to 39 months

  32. Incidence of anti-drug antibodies (ADAs) to linvoseltamab over time

    Time frame: Up to 39 months

  33. Titers of ADAs to linvoseltamab over time

    Time frame: Up to 39 months

07

Study locations

20 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Aug 2028, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Mar 5, 2024
StartActual
Aug 7, 2024
Primary completionEst.
Aug 20, 2028
CompletionEst.
Feb 20, 2035
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06292780
Responsible party
Sponsor
First posted
Mar 5, 2024
Start date
Aug 7, 2024
Primary completion
Aug 20, 2028 (estimated)
Completion
Feb 20, 2035 (estimated)
Last update
Aug 18, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linvoseltamab

Start the discussion